Osiris Therapeutics, Inc. , announced today that the manuscript from its multi-center , randomized, controlled clinical trial comparing the safety and effectiveness of GrafixA to control in patients with chronic diabetic foot ulcers has been accepted for publication in the International Wound Journal.
http://ift.tt/Ugbi4O
http://ift.tt/Ugbi4O
No comments:
Post a Comment